Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances

References

• Consroe P, Musty R, Rein J et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol.38, 44–48 (1997).
   PubMed Web of Science ®Google Scholar
• Woolridge E, Barton S, Samuel J et al. Cannabis use in HIV for pain and other medical symptoms. J. Pain Symptom Manage.29, 358–368 (2005).
   PubMed Web of Science ®Google Scholar
• Smith PF. Sativex® (GW-1000). Curr. Opin. Investig. Drugs5, 748–754 (2004).
   PubMedGoogle Scholar
• Rice AS. Cannabinoids and pain. Curr. Opin. Investig. Drugs2, 399–414 (2001).
   PubMedGoogle Scholar
• Pertwee RG. Cannabinoid receptors and pain. Prog. Neurobiol.63, 569–611 (2001).
   PubMed Web of Science ®Google Scholar
• Kreitzer AC, Regehr WG. Retrograde signalling by endocannabinoids. Curr. Opin. Neurobiol.12, 324–330 (2002).
   PubMed Web of Science ®Google Scholar
• Alger BE. Retrograde signalling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol.68, 247–286 (2002).
   PubMed Web of Science ®Google Scholar
• Ashton JC. Cannabinoids for the treatment of inflammation. Curr. Opin. Invest. Drugs8, 373–384 (2007).
   PubMed Web of Science ®Google Scholar
• Eljasschewitsch E, Witting A, Mawrin C et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron49, 67–79 (2006).
   PubMedGoogle Scholar
• Achiron A, Miron S, Lavie V et al. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol.102, 26–31 (2000).
   PubMed Web of Science ®Google Scholar
• Baker D, Pryce G, Croxford JL et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J.15, 300–302 (2001).
   PubMed Web of Science ®Google Scholar
• Baker D, Pryce G, Croxford JL et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature404, 84–87 (2000).
   PubMed Web of Science ®Google Scholar
• Berrendero F, Sanchez A, Cabranes A et al. Changes in cannabinoid (CB1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse41, 195–202 (2001).
   PubMed Web of Science ®Google Scholar
• Benito C, Romero JP, Tolon RM et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are aare specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci.27(9), 2396–2402 (2007).
   PubMed Web of Science ®Google Scholar
• Campbell FA, Tramer MR, Carroll et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br. Med. J.323, 13–16 (2001).
   PubMed Web of Science ®Google Scholar
• Tramer MR, Caroll D, Campbell FA et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. Br. Med. J.323, 16–21 (2001).
   PubMed Web of Science ®Google Scholar
• Notcutt W, Price M, Miller R et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia59, 440–452 (2004).
   PubMed Web of Science ®Google Scholar
• Buggy DJ, Toogood L, Maric S et al. Lack of analgesic efficacy of oral Δ-9-tetrahydrocannabinol in post-operative pain. Pain106,169–172 (2003).
   PubMed Web of Science ®Google Scholar
• Attal N, Brasseur L, Guirimand D et al. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur. J. Pain8,173–177 (2004).
   PubMed Web of Science ®Google Scholar
• Naef M, Curatolo M, Petersen-Felix S et al. The analgesic effect or oral Δ-9-tetrahydrocannabinol (THC), morphine and a THC and morphine combination in healthy subjects under experimental pain conditions. Pain105, 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Killestein J, Hoogervorst ELJ, Reif M et al. Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology58, 1404–1407 (2002).
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre, randomised placebo-controlled trial. Lancet362, 1517–1526 (2003).
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Sanders HP, Wright DE et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J. Neurol. Neurosurg. Psychiatr.76, 1664–1669 (2005).
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double-blind placebo controlled crossover trial. Br. Med. J.329, 253–261 (2004).
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil.17, 21–29 (2003).
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler.10, 434–441 (2004).
   PubMed Web of Science ®Google Scholar
• Vaney C, Heinzel-Gutenbrunner M, Jobin P et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler.10, 417–424 (2004).
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology65, 812–819 (2005).
   PubMed Web of Science ®Google Scholar
• Blake DR, Robson P, Ho M et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex®) in the treatment of pain caused by rheumatoid arthritis. Rheumatology45, 50–52 (2006).
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela PM, House H et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler.12, 639–645 (2006).
   PubMed Web of Science ®Google Scholar
• Colin C, Davies P, Mutiboko IK et al. Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol.14, 290–296 (2007).
   PubMedGoogle Scholar
• Fox P, Bain PG, Glickman S et al. The effects of cannabis on tremor in patients with multiple sclerosis. Neurology62, 1105–1109 (2004).
   PubMed Web of Science ®Google Scholar
• Holdcroft A, Maze M, Dore C et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for post-operative pain management. Anesthesiology104, 1040–1046 (2006).
   PubMed Web of Science ®Google Scholar
• Abrams DI, Jay CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy. Neurology68, 515–521 (2007).
   PubMed Web of Science ®Google Scholar
• Kaarst M, Salim K, Burtsein S et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled study. JAMA290, 1757–1762 (2003).
   PubMedGoogle Scholar
• Wissel J, Haydn T, Muller J et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. J. Neurol.253, 1337–1341 (2006).
   PubMed Web of Science ®Google Scholar
• Brady CM, DasGupta R, Dalton C et al. An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler.10, 425–433 (2004).
   PubMed Web of Science ®Google Scholar
• Freeman RM, Adekanmi O, Waterfield MR et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int. Urogynecol. J. Pelvic Floor Dysfunct.17, 636–641 (2006).
   PubMed Web of Science ®Google Scholar
• Killestein J, Polman C. The therapeutic value of cannabinoids in MS: real or imaginary? Mult. Scler.10, 339–340 (2004).
   PubMed Web of Science ®Google Scholar
• Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev.4, CD001332 (2000).
   Google Scholar
• Chan GCK, Hinde TR, Impey S et al. Hippocampal neurotoxicity of Δ-9-tetrhydrocannabinol. J. Neurosci.18, 5322–5332 (1998).
   PubMed Web of Science ®Google Scholar
• Nagayama T, Sinor AD, Chen J et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci.19, 2987–2995 (1999).
   PubMed Web of Science ®Google Scholar
• McKallip RJ, Lombard C, Fisher M et al. Δ-9-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo.J. Pharmacol. Exp. Therap.302, 451–465 (2002).
   PubMed Web of Science ®Google Scholar
• El-Gohary M, Eid MA. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum. Exp. Toxicol.23, 149–156 (2004).
   PubMed Web of Science ®Google Scholar
• Abrams DI, Hilton JF, Leiser RJ et al. Short-term effects of cannabinoids in patients with HIV-1 infection. Ann. Intern. Med.139, 258–266 (2003).
   PubMed Web of Science ®Google Scholar
• Beal JE, Olson R, Lefkowitz L et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome associated anorexia. J. Pain Symptom Manage.14, 7–14 (1997).
   PubMed Web of Science ®Google Scholar
• Pope HG, Gruber AJ, Hudson JI et al. Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiat.58, 909–915 (2001).
   PubMed Web of Science ®Google Scholar
• Pope HG, Gruber AJ, Yurgelun-Todd D. Residual neuropsychological effects of cannabis. Curr. Psych. Rep.3, 507–512 (2001).
   PubMedGoogle Scholar
• Jager G, Kahn RS, Van Den Brink W et al. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacol. (Berl.)185, 358–368 (2006).
   PubMed Web of Science ®Google Scholar
• Fried PA, Watksinson B. Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol.23, 421–430 (2001).
   PubMed Web of Science ®Google Scholar
• Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol. Teratol.23, 1–11 (2001).
   PubMed Web of Science ®Google Scholar
• Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16 year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol.25, 427–436 (2003).
   PubMed Web of Science ®Google Scholar
• Goldschmidt L, Richardson GA, Cornelius MD et al. Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol. Teratol.26, 521–532 (2004).
   PubMed Web of Science ®Google Scholar
• Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol. Teratol.22, 325–336 (2000).
   PubMed Web of Science ®Google Scholar
• Smith AM, Fried PA, Hogan MJ et al. Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. Neurotoxicol. Teratol.26, 533–542 (2004).
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Tennant C, Gilmour S et al. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10 month prospective study. Psychol. Med.37(7), 927–934 (2007).
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood J, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction100, 354–366 (2005).
   PubMed Web of Science ®Google Scholar
• Henquet C, Krabbendam L, Spauwen J et al. Prospective cohort study of cannabis use, predisposition for psychosis and psychotic symptoms in young people. Br. Med. J.330, 11–16 (2005).
   PubMed Web of Science ®Google Scholar
• Rossler W, Riecher-Rossler A, Angst J et al. Psychotic experiences in the general population: a twenty year prospective community study. Schiz. Res.92, 1–14 (2007).
   PubMed Web of Science ®Google Scholar
• Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene x environment interaction. Biol. Psychiatry57, 1117–1127 (2005).
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD et al. Abstinence symptoms following oral THC administration in humans. Psychopharmacol. (Berl.)141, 385–404 (1999).
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD et al. Abstinence symptoms following smoked marijuana in humans. Psychopharmacol. (Berl.)141, 395–404 (1999).
   PubMed Web of Science ®Google Scholar
• Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction97, 621–632 (2002).
   PubMed Web of Science ®Google Scholar
• Tanda G, Goldberg SR. Cannabinoids: reward, dependence and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacol. (Berl.)169, 115–134 (2003).
   PubMedGoogle Scholar